Ocean Biomedical faces Nasdaq delisting; CFO and director resign

Ocean Biomedical, Inc.

Nasdaq Board declined to review Listing Council decision; final delisting action triggered under Rule 5830 and SEC Rule 12d2-2.
Director Michael Petersen resigned effective August 31, 2025; no disagreement cited.
CFO Jolie Kahn resigned effective August 5, 2025; no disagreement cited.
Company continues to work on previously announced power and cryptocurrency strategies.

item 3.01item 5.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.